CEO Talk In the second part of this two-part interview, the chairman of TTY looks back at his experiences in the Taiwanese market, and assess what could have been done differently with his company. He also offers advice to the next generation of Taiwanese pharmaceutical companies. To read the first part of…
Array In Taiwan, biotech is finally booming, and more and more of the companies benefitting from this boom are listing on the Gre Tai Securities Market (GTSM), built with small to medium enterprises in mind, and tailored for companies that are part of emerging industries. But are these companies overvalued, and…
Neopharma BR Shetty, CEO of NMC Health, talks about the importance of fostering local talent—one of the biggest challenges of the region— building a company in the UAE, and where he sees the future of the company going. What did the progression and evolution of NMC Health look like, from…
Life Sciences Wayne Samuels, partner at PwC Canada, discusses the most pressing issues in the country’s healthcare system and pharmaceutical industry, and outlines the changing dynamics in Canada’s pharma business model. What have been some of the key developments in life sciences during your tenure at PwC Canada so far? The most…
Intellectual Property Michael Seckler of Ferring Canada offers his input about the affiliate’s recent restructuring, as well as the challenges of Canada’s reimbursement and pricing schemes and the advantages of the company’s unique “built-in competitive IP”. What have been your initial impressions of the Canadian pharmaceutical market since you joined last October?…
Pharmaceutical Industry Technology and Development Center (PITDC) The president of Pharmaceutical Industry Technology and Development Center (PITDC) considers the company’s need to remain an international competitor and how to achieve it, the gap in new drug development in Taiwan, and PITDC’s mission to bring the country’s domestic companies to the international level. What are your thoughts on…
Biopharmaceutical Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty pharma using Canada’s strong clinical base. What do Canadian biopharmaceutical companies offer as a competitive edge? I believe we have…
Biopharmaceutical Hervé Lilliu, General Manager of UCB Canada, describes Canada’s need to support the global pharma-ceutical industry rather than vice versa, and highlights examples of ways in which Canada’s slumbering R&D investment levels can be brought back to the country. What was your initial mandate upon arriving at UCB and what…
investment The Deputy Executive Secretary of Taiwan’s National Development Fund discusses the recent shift in focus from semiconductors to biotech investments; why this has been a huge success thus far and why international collaboration will further benefit the market in Taiwan. Over the years, the National Development Fund (NDF) has increasingly…
Biopharmaceuticals Over the past decade since its founding, what are some of the highlights in the transformation of Taiwan Advance Bio-Pharmaceutical Inc. (TABP) into a well established company? TABP was founded in 2000 as a spinoff of the Development Center for Biotechnology (DCB). The DCB was established in 1984 to support…
Generics In the first part of this two-part interview, the Chairman of TTY Biopharm considers the success of his long-term strategy to streamline TTY’s portfolio and focus on the company’s strengths, and talks about the opportunities in Asia for companies that have followed a similar path to TTY. To read the…
GGD The co-managing partner of one of Canada’s leading IP law firms discusses the landscape for intellectual property in the pharmaceutical industry in Canada today, the legislative challenges facing his clients, and the incentive schemes in place to bring innovation to Canada. What have you seen as the key trends of…
See our Cookie Privacy Policy Here
